- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05102448
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
October 19, 2021 updated by: Jiang lindi, Shanghai Zhongshan Hospital
Comparison of the Efficacy and Safety of Tofacitinib and Methotrexate Based on Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Trial
The aim of this study is to evaluate and compare the efficacy and safety of tofacitinib and methotrexate based on prednisone therapy in patients with Takayasu arteritis
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Takayasu's arteritis (TAK), a chronic large vessel vasculitis, involves the aorta and its main branches.
Glucocorticoids and immunosuppressants such as methotrexate, cyclophosphamide are common agents for TAK treatment.
However, their effects for remission induction and relapse prevention are not satisfied.
More effective agents for TAK treatment remain to be investigated.
Tofacitinib (TOF) is a Jak inhibitor, which has been proved to be effective in multiple autoimmune diseases such as rheumatoid arthritis.
Our preliminary real-world study also demonstrated a promising treatment effect of TOF in patients with TAK.
But its efficacy and safety needs further verification.
The present randomized controlled trial aimes to compare efficacy between methotrexate and tofacitinib in TAK treatment.
Study Type
Interventional
Enrollment (Anticipated)
76
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lindi Jiang, Ph.D., M.D.
- Phone Number: 2471 021-64041990
- Email: zsh-rheum@hotmail.com
Study Contact Backup
- Name: Xiufang Kong, Ph.D., M.D.
- Phone Number: 2471 021-64041990
- Email: kongxiufang2007@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Lindi Jiang
-
Contact:
- Lindi Jiang, Ph.D
- Phone Number: 86-02164041990
- Email: zsh-rheum@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients met 1990 American College of Rheumatology (ACR) classification criteria or 2018 ACR classification criteria (draft) of TAK
- Women or men aged 18-65
- All patients agreed that there is no fertility plan during clinical trials, and the results of female serum or urinary pregnancy tests must be negative
- Active TAK patients according to NIH disease activity criteria
- All patients agreed to sign the informed consent
Exclusion Criteria:
Patients with organ failure who accord to one or more of the following conditions:
I.Heart function New York class 4 II.Glomerular filtration rate ≤ 60ml/min III.Liver function Child grade 2 and above IV.High-frequency melanoma (attacks for 3 consecutive days) V.Acute cerebral infarction or cerebral hemorrhage VI.Blood pressure > 160/100mmHg
- Patients who received revascularization surgery related to the treatment of TAK within 3 months (except balloon dilatation); balloon dilatation or surgery unrelated to TAK within 1 month
- Patients who have other autoimmune diseases (e.g. ANCA-associated vasculitis, systemic lupus erythematosus, Behcet's disease, etc.)
- Patients with severe, progressive or uncontrolled comorbidities of kidney, liver, blood system, gastrointestinal, lung, heart, etc or other coexisting medical conditions that may exert unexpected risks
- Patients with concomitant diseases, such as asthma, that may require additional medium to high doses of glucocorticoids (prednisone ≥ 10mg/ days or equivalent dose) during the study period
- Patients with active infections with HBV, HCV, tuberculosis or other serious acute or chronic infections
- Patients with malignancies
- Patients with one or more of the following abnormal laboratory examinations I.Serum ALT or AST ≥ 1.5 times the normal upper limit; II.White blood cell count ≤ 4 × 109/L III.Platelet count ≤ 100x109/L IV.Hemoglobin < 85g/L V.Other abnormal laboratory tests that may cause unacceptable risks
- Patients allergic to the experimental drug
- Patients who have ever failed to tofacitinib or methotrexate after 3 months' treatment in previous medical history
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tofacitinib
Partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.
|
Other Names:
|
Active Comparator: Methotrexate
Participates would be given tablets of methotrexate (2.5mg per tablet) 15mg each week, the treatment duration will last 12 months during the whole follow-up period.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effectiveness rate after 6 months' treatment
Time Frame: From the enrollment to the end of 6 months
|
The effectiveness rate equals to patients who achieved this goal /patients at the end of 6 months.
The effectiveness was defined as satisfying three of the following 1)-4) criteria and the 5) criteria: 1) no systemic symptoms such as weakness, weight loss, etc; 2) no new ischemic symptoms or signs; 3) normal erythrocyte sedimentation rate (ESR); 4) no new vascular progression or new lesions upon imaging; 5) GCs is tapered to 10mg qd and this dosage is maintained for 4 weeks.
|
From the enrollment to the end of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The remission rate with GCs 5mg qd at the end of 12 months
Time Frame: From the enrollment to the the end of 12 months
|
Ratio of patients who achieved remission with GCs 5mg qd at the end of 12 months.
The remission is defined as satisfying three of the following 1)-4) criteria: 1) no systemic symptoms such as weakness, weight loss, etc; 2) no new ischemic symptoms or signs; 3) normal erythrocyte sedimentation rate (ESR); 4) no new vascular progression or new lesions upon imaging.
It is required that GCs 5mg qd should be maintained at least for four weeks.
|
From the enrollment to the the end of 12 months
|
The remission rate with GCs 0mg qd at the end of 12 months
Time Frame: From the enrollment to the the end of 12 months
|
Ratio of patients who achieved remission with GCs 0mg qd at the end of 12 months.
The remission is defined as satisfying three of the following 1)-4) criteria: 1) no systemic symptoms such as weakness, weight loss, etc; 2) no new ischemic symptoms or signs; 3) normal erythrocyte sedimentation rate (ESR); 4) no new vascular progression or new lesions upon imaging.
It is required that GCs 0mg qd should be maintained at least for four weeks.
|
From the enrollment to the the end of 12 months
|
Relapse free survival rate
Time Frame: From the enrollment to the the end of 12 month
|
Ratio of patients without relapse after achieving remission during the 12 months follow-up
|
From the enrollment to the the end of 12 month
|
The cumulative dosage of GCs during the whole period of 12-months follow-up
Time Frame: From the enrollment to the the end of 12 months
|
The cumulative dosage = Sum of doses of prednisone (or equivalents) each day
|
From the enrollment to the the end of 12 months
|
Side effects rate
Time Frame: From the enrollment to the the end of 12 months
|
Ratio of patients with side effects.
All the kinds of adverse event related to the treatment and the disease itself will be recorded.
|
From the enrollment to the the end of 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Lindi Jiang, Ph.D., M.D., Department of Rheumatology in Zhongshan hospital, Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2021
Primary Completion (Anticipated)
December 31, 2025
Study Completion (Anticipated)
December 31, 2025
Study Registration Dates
First Submitted
October 19, 2021
First Submitted That Met QC Criteria
October 19, 2021
First Posted (Actual)
November 1, 2021
Study Record Updates
Last Update Posted (Actual)
November 1, 2021
Last Update Submitted That Met QC Criteria
October 19, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Vasculitis
- Skin Diseases, Vascular
- Aortic Diseases
- Arteritis
- Takayasu Arteritis
- Aortic Arch Syndromes
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Protein Kinase Inhibitors
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
- Tofacitinib
Other Study ID Numbers
- TACTIC-TM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Takayasu Arteritis
-
Assistance Publique - Hôpitaux de ParisChugai PharmaceuticalCompleted
-
Instituto Nacional de Cardiologia Ignacio ChavezCompleted
-
AbbVieActive, not recruitingTakayasu Arteritis (TAK)Argentina, Brazil, China, Japan, Korea, Republic of, Turkey
-
Assistance Publique - Hôpitaux de ParisRecruitingArteritis | Systemic Vasculitis | Arteritis, TakayasuFrance
-
Chinese Pulmonary Vascular Disease Research GroupRecruitingTakayasu Arteritis With Pulmonary Artery Involvement | Percutaneous Transluminal Pulmonary Angioplasty | PAH Targeted MedicationChina
-
Beijing Institute of Heart, Lung and Blood Vessel...Peking University People's Hospital; Shanghai Zhongshan HospitalRecruiting
-
University of Sao PauloFederal University of São PauloUnknown
-
University of PennsylvaniaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedTakayasu's ArteritisUnited States, Canada
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
Clinical Trials on Tofacitinib
-
PfizerCompletedAnkylosing SpondylitisKorea, Republic of, United States, Spain, Taiwan, Canada, Czech Republic, Poland, Hungary, Germany, Russian Federation
-
PfizerCompleted
-
PfizerCompletedPlaque PsoriasisUnited States
-
PfizerCompleted
-
Nanfang Hospital of Southern Medical UniversityJiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingRheumatoid Arthritis
-
PfizerCompleted
-
PfizerCompletedJuvenile Idiopathic ArthritisUnited States, Spain, Turkey, Canada, Australia, Israel, United Kingdom, Argentina, Brazil, Poland, Mexico, Belgium, Russian Federation, Ukraine
-
Stanford UniversityNational Institutes of Health (NIH)RecruitingDiaphragm InjuryUnited States